NMN vs NR: Which NAD+ Precursor Actually Works in 2026?
NMN vs NR — the bioavailability data, the Sinclair vs Imai positions, the RCTs that exist, the FDA situation, and an honest dose-by-dose comparison.
NAD+ — nicotinamide adenine dinucleotide — sits at the center of every metabolic reaction in your body. It falls roughly 50% between age 20 and age 60. The longevity field's question for the last decade has been simple: can you put it back?
Two molecules have absorbed most of the answer. NMN (nicotinamide mononucleotide), championed by David Sinclair at Harvard. NR (nicotinamide riboside), commercialized by Charles Brenner and ChromaDex as Niagen. Both raise NAD+ in blood. Both are sold by the ton. Neither has been shown to extend a human life.
This is what the data actually says.
The Biochemistry Most Marketing Skips
NAD+ is regenerated through three pathways: de novo synthesis (from tryptophan), the Preiss-Handler pathway (from niacin), and the salvage pathway (from nicotinamide, NR, and NMN). The salvage pathway handles roughly 85% of NAD+ turnover in adult mammals.
NR is converted to NMN by the enzyme NRK (nicotinamide riboside kinase). NMN is then converted to NAD+ by NMNAT. So NR sits one step earlier in the pathway than NMN. Both arrive at the same destination.
The contested question is whether NMN can enter cells directly as NMN, or whether it must be hydrolyzed to NR first at the cell membrane. Imai's group at Washington University published a 2019 paper in Nature Metabolism identifying Slc12a8 as a direct NMN transporter. Charles Brenner's group published a rebuttal arguing the data did not replicate. The biochemical question matters less than supplement marketers suggest — what matters clinically is whether oral dosing raises tissue NAD+. Both compounds do.
The Human Trials That Actually Exist
For NR, the strongest data is Martens 2018 in Nature Communications: 12 weeks of 500mg NR daily in 30 middle-aged adults elevated whole-blood NAD+ by approximately 60% and reduced systolic blood pressure by 8 mmHg in those with elevated baseline pressure. Dollerup 2018 tested 1000mg twice daily in obese men — well-tolerated, elevated NAD+, but no improvement in insulin sensitivity at that dose.
For NMN, the most-cited human data is Yoshino 2021 in Science: 25 postmenopausal women with prediabetes received 250mg NMN daily for 10 weeks. Muscle insulin sensitivity improved by 25%. NAD+ in skeletal muscle rose measurably. Whole-blood NAD+ rose ~38%. The trial was small (n=25), single-center, and in a specific population.
Several other small NMN trials exist (Irie 2020 in Japanese men, Yamane 2023 in healthy older adults). All show NAD+ elevation. None show the clinical endpoints that would make NMN a verified longevity intervention. Same is true on the NR side.
The mismatch between what the trials show and what supplement marketing claims is large. The trials show a biomarker moves. The marketing implies the biomarker moving means the human ages slower. That second step has not been demonstrated.
FDA Status and the Niagen Advantage
In October 2022, the FDA notified NMN supplement manufacturers that NMN no longer qualifies as a dietary supplement under DSHEA, because Metro International Biotech had filed an investigational new drug application using NMN. This triggered the so-called "drug preclusion clause" — once a substance is authorized for drug investigation before being marketed as a supplement, it cannot subsequently be sold as one.
NR (specifically as nicotinamide riboside chloride, branded Niagen) was already GRAS-affirmed before any IND. It remains a compliant supplement. ChromaDex holds the dominant IP position.
The practical result: NR has cleaner regulatory standing in the U.S. NMN is still widely sold, but technically out of compliance. International suppliers continue to ship; FDA enforcement has been inconsistent. For men who prioritize regulatory clarity, NR is the lower-risk path. For men who prioritize raw NAD+ elevation and tolerate the regulatory ambiguity, NMN is fine pharmacologically.
Both compounds raise the laboratory marker. Neither has been shown to extend a single human life. That gap is the honest center of the conversation.
Dose, Cost, and Realistic Expectations
Functional dosing based on the human trial data:
- NR: 250–500mg/day. Niagen-branded products are the most-studied; quality on no-name NR is variable.
- NMN: 250–1000mg/day. Standard biohacker protocol is 500mg–1g. Sublingual NMN is marketed as superior but has no controlled bioavailability data over oral capsules.
Both compounds plateau in NAD+ elevation around 1000mg/day. Higher doses do not produce further elevation in the published pharmacokinetic data.
Costs vary widely. NR (Niagen) typically runs $40–80/month at 250mg. NMN ranges from $30 (low-purity, often under-dosed) to $80+ (third-party tested). Third-party purity testing (Certificate of Analysis from an independent lab) is non-negotiable — NMN in particular has had documented purity issues in retail products.
What to expect at the 8–12 week mark: a measurable rise in whole-blood NAD+ if you test (commercial assays through Quest Diagnostics or Jinfiniti). Subjective effects are inconsistent and mostly placebo-magnitude in controlled comparison. Men who feel "more energy" from NAD+ precursors are not lying — they are also not differentiable from placebo in the trials.
The Honest Position
The longevity case for NAD+ precursors rests on mechanism (NAD+ falls with age; sirtuins, PARPs, and CD38 all use NAD+ as a substrate) and animal data (rodent lifespan increases of 5–15% in some NR/NMN studies, no effect in others). The human bridge is missing.
Neither Sinclair nor Imai has produced a human trial showing reversal of biological age on a validated clock (Horvath, GrimAge, DunedinPACE) attributable to NMN. Charles Brenner has consistently been the most cautious public voice on NR's longevity claims — and he developed the compound.
The reasonable position: NAD+ precursors are a plausible bet with low downside (both are well-tolerated up to 1g/day) and undemonstrated upside. They should not displace foundational interventions — VO2 max, ApoB management, sleep, muscle mass, strength — that have actual all-cause mortality data behind them.
The Protocol
- Choose one, not both: NR if you want regulatory clarity and the larger published RCT base. NMN if you want the Imai-Sinclair pathway and accept the FDA gray zone.
- Dose: 500mg/day for either. Start there. No published data supports going higher.
- Timing: Morning, with food. NAD+ precursors briefly stress one-carbon metabolism — taking them at night has been associated with sleep disruption in some users.
- Quality: Demand a Certificate of Analysis from an independent lab (Eurofins, Labdoor, ConsumerLab). For NMN especially, retail purity ranges from 60% to 99%+.
- Cycle: 5 days on, 2 days off — anecdotally common in biohacker protocols, mechanistically unjustified, not formally tested.
- Stack with TMG: 500mg trimethylglycine (betaine) per day. Both NMN and NR donate methyl groups during NAD+ turnover; TMG replenishes the methyl pool. This is a reasonable precaution, not a proven requirement.
- Track: If you are paying for this, pay for the NAD+ test. Jinfiniti and Quest both offer whole-blood NAD+ assays. Baseline before starting, retest at 8 weeks. If the biomarker did not move, the supplement did not work for you.
Key Takeaways
- NMN and NR both raise whole-blood NAD+ by 40–90% at standard doses; the molecular path differs but the destination is identical.
- NR has more published human RCT evidence; NMN has stronger marketing and the Sinclair endorsement.
- FDA reclassified NMN out of supplement legal status in late 2022; NR (as Niagen) remains compliant.
- No human trial to date demonstrates lifespan extension, biological age reversal, or hard clinical endpoint improvement from either.
- Pick one, dose at 500mg, verify purity, retest NAD+ at 8 weeks. Do not displace the interventions with actual mortality data behind them.
Want to know whether your biomarkers actually support longevity-spend? → Take the PrimalPrime Biological Age Calculator before you spend on precursors.